CTIS2023-503714-77-00进行中（未招募）1 期
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation - 849-017
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 137
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation. a.Cohort A* (closed): squamous or nonsquamous histology b.Cohorts C and E*: nonsquamous histology only
排除标准
- •Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy (CIT in Cohorts A and E only), any therapy targeting KRAS G12C mutation (eg, sotorasib) , or received maintenance therapy, eg, pembrolizumab and/or pemetrexed following completion 4-6 cycles of a platinum-based regimen administered in the first-line setting (Cohort C only), Radiation to the lung > 30 Gy within 6 months prior to first dose of study treatment., Active brain metastases.
研究者
相似试验
进行中（未招募）
不适用
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004966-33-BEZ Brussel
进行中（未招募）
1 期
Research into a new treatment for children and young adults with diffuse midline gliomaEUCTR2022-000636-40-NLPacific Pediatric Neuro-Oncology Consortium (PNOC)324
招募中
2 期
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of ProgressioDiffuse midline glioma'sHigh grade brain tumors10029211NL-OMON53539Prinses Máxima Centrum voor Kinderoncologie30
招募中
1 期
PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of ProgressioDiffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)MedDRA version: 25.1Level: LLTClassification code: 10087678Term: Diffuse midline glioma H3K27M mutation Class: 100000004848MedDRA version: 21.1Level: PTClassification code: 10065443Term: Malignant glioma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10080666Term: Diffuse intrinsic pontine glioma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10006143Term: Brain stem glioma Class: 100000004864CTIS2023-507598-16-00Prinses Maxima Centrum voor Kinderoncologie B.V.324
进行中（未招募）
1 期
Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastomarecurrent glioblastomaMedDRA version: 19.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000200-23-BEZ Brussel54